By David Bautz, PhD
OTC:VIVXF
READ THE FULL VIVXF RESEARCH REPORT
Business Update
OxC-beta Approved in Vietnam; Looking for Sales Ramp in 2H22
Avivagen, Inc. (OTC:VIVXF) is developing products to support animal health, which includes replacing antibiotics in livestock feeds with proprietary compounds that promote the growth and overall health of the animal through support of the host's innate immune system. Avivagen discovered that β-carotene polymerizes with oxygen into a unique class of compounds (oxidized β-carotene, OxBC) that promote immunological health and are the basis of Avivagen's OxC-beta™ technology. Numerous studies conducted by Avivagen and...
Login or create a forever free account to read this news
Sign up/Log in